Results of the COLCORONA study published in The Lancet Respiratory Medicine
(University of Montreal) Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news
Management of severe covid-19: progress and promise, BMJ
This BMJ editorial outlines the current therapeutic approaches noting there is no evidence to support vitamins C and D, zinc, lopinavir-ritonavir, colchicine, interferons, fluvoxamine, ivermectin, and convalescent plasma; and survival benefit only reported with glucocorticoids. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 11, 2021 Category: Consumer Health News Source Type: news
Case report: colchicine toxicokinetic analysis in a poisoned child requiring extracorporeal life support - P érez Marín M, Prod'hom S, de Villiers SF, Ferry T, Amiet V, Natterer J, Perez MH, Buclin T, Chtioui H, Longchamp D.
Colchicine poisoning is associated with a poor prognosis, especially when leading to shock and multi-organ failure, and management is limited to supportive care, including multiple-dose activated charcoal. At therapeutic concentrations, colchicine eliminat... (Source: SafetyLit)
Source: SafetyLit - April 28, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Colchicine for Secondary Prevention in Coronary Disease Colchicine for Secondary Prevention in Coronary Disease
Two new studies provide evidence supporting the cardiovascular benefits of once-daily colchicine in coronary disease.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19, Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial
Preliminary analysis found no significant difference in 28-day mortality (20% colchicine vs. 19% usual care alone; risk ratio 1.02 [95% CI 0.94-1.11]; p=0.63). On the advice of the independent Data Monitoring Committee, recruitment to this arm of the study has closed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 9, 2021 Category: Consumer Health News Source Type: news
RECOVERY Trial of COVID Treatments Stops Colchicine Arm RECOVERY Trial of COVID Treatments Stops Colchicine Arm
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 5, 2021 Category: Intensive Care Tags: Cardiology News Source Type: news
Scientists will test whether gout drug helps infected adults beat Covid symptoms
Oxford University researchers have begun trials on 30p pill colchicine today to examine whether it can reduce recovery time from Covid and prevent the need for hospital admission. (Source: the Mail online | Health)
Source: the Mail online | Health - March 3, 2021 Category: Consumer Health News Source Type: news
Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients, MHRA
Colchicine should not be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 16, 2021 Category: Consumer Health News Source Type: news
Covid-19 Therapeutic Alert: Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients - Trial Use Only, MHRA (published 12th February 2021)
Colchicine should NOT be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use. Although early trial data is potentially promising, further evaluation of study data is needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 15, 2021 Category: Consumer Health News Source Type: news
Colchicine Post-MI: Close but No Cigar Colchicine Post-MI: Close but No Cigar
The inflammatory hypothesis of coronary artery disease has gained traction, but prescribing drugs with anti-inflammatory effects has yet to take off. Could recent data on colchicine change that?theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
ColCORONA: More Questions Than Answers for Colchicine in COVID-19 ColCORONA: More Questions Than Answers for Colchicine in COVID-19
Millions of dollars and thousands of patients later, the phase 3 study highlights the challenges of COVID-19-related preprint studies without peer review.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 8, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Experience sharing on treatment of an acute colchicine poisoning patient - Jiang Q, Li S, Yang Z, Liu F, Wang P, Wang J, Zhao H.
Colchicine is mainly used in the treatment of acute gout attack, acute attack of chronic gout and other diseases in clinic. But the drug has high toxicity (highly toxic), the therapeutic dose is very close to the toxic dose, and there is no special effect ... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Small Study Tests Colchicine for Moderate-to-Severe COVID-19
FRIDAY, Feb. 5, 2021 -- For patients with moderate-to-severe COVID-19, colchicine reduces the length of supplemental oxygen therapy and hospitalization, according to a study published online Feb. 4 in RMD Open.
Maria Isabel Lopes, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2021 Category: Pharmaceuticals Source Type: news
Little evidence that colchicine benefits COVID-19 patients, Quebec advisory panel finds
Quebec government clinical experts say there isn't enough evidence to recommend widespread use of the popular gout medication to treat COVID-19 patients, dampening hopes the drug could be a short-term tool to reduce hospitalizations and deaths. (Source: CBC | Health)
Source: CBC | Health - February 5, 2021 Category: Consumer Health News Tags: News/Canada/Montreal Source Type: news
Gout can be used to cut hospital times for coronavirus by reducing the need for oxygen therapy
Brazilian researchers found colchicine, which is used to treat gout, helped reduce the need for oxygen therapy by more than a third in hospital coronavirus cases in a 75-patient study. (Source: the Mail online | Health)
Source: the Mail online | Health - February 4, 2021 Category: Consumer Health News Source Type: news
